After initial excitement about the discovery of a promising treatment for some coronavirus patients, executives with Gilead Sciences are now facing harsh criticism over the initial business decisions they’ve made in the midst of a pandemic.
Gilead also announced this week that it would investigate the less-expensive alternative to remdesivir after the company faced accusations of suppressing it for financial considerations. The spokesperson said the company has since “initiated additional preclinical studies to further compare remdesivir and GS-441524” and will publish the results of those studies “as soon as they become available.”
Led by California Democrat Xavier Becerra and Louisiana Republican Jeff Landry, the attorneys general encouraged the federal government to invoke a law that would allow third parties to develop remdesivir, effectively waiving Gilead’s patent. Critics of Gilead say their concern stems in part from what they say is the relatively low cost of manufacturing the drug. The state attorneys general claim one vial of the drug – a daily dose – costs between $1 and $12 to manufacture. One peer-reviewed study published in the Journal of Virus Eradication earlier this year suggested that one dose could be produced for only 93 cents.
Beyond the medicine’s potential health benefits, Gilead highlight’s its value in saving hospital costs, while acknowledging that “there is no playbook for how to price a new medicine in a pandemic.”
If you are in good health, you don't need any medicine...just 14 days self quarantine. This is for the desperate who are in poor health. This shit will probably give you cancer in the long run. I SAY NO TO ANY COVID-19 DRUG!
इंडिया ताज़ा खबर, इंडिया मुख्य बातें
Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।
स्रोत: Reuters - 🏆 2. / 97 और पढो »